Today: 26 March 2026
Subscribe
Browse Category

Stock Market 9 January 2026

Aristocrat Leisure stock rises after A$750 million buyback top-up — what investors watch next

Aristocrat Leisure stock rises after A$750 million buyback top-up — what investors watch next

Aristocrat Leisure shares closed up 1.0% at A$57.22 after the board added A$750 million to its buyback, raising total capacity to A$1.5 billion. Citi lifted earnings-per-share forecasts by up to 1% for fiscal 2026–2028 following the move. The S&P/ASX 200 slipped three points to 8,716. Investors await Aristocrat’s AGM on Feb. 19 and interim results on May 13.
9 January 2026
··
Northern Star Resources stock edges up after ASX query response keeps costs in focus

Northern Star Resources stock edges up after ASX query response keeps costs in focus

Northern Star Resources shares rose 0.5% to A$24.72 after the company said it cannot yet quantify how a weaker December quarter will affect annual costs. The miner cut its FY26 gold sales guidance on Jan. 2, citing plant issues and lower ore grades. Northern Star told the ASX it will update cost guidance once data is confirmed. The S&P/ASX 200 closed down three points at 8,716.
9 January 2026
··
DroneShield (ASX:DRO) stock jumps after Trump defense-budget push — what investors watch next

DroneShield (ASX:DRO) stock jumps after Trump defense-budget push — what investors watch next

DroneShield shares closed up 4.4% at A$4.02 Friday, with turnover more than doubling to 21.3 million shares. The rally followed U.S. President Trump’s call for higher military spending, which lifted defence stocks globally. Peers like Austal also gained in Australia. Investors await U.S. jobs data and further sector moves at Monday’s ASX open.
9 January 2026
····
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 09.01.2026

Valero Energy closed at $185.28, about 39% below its DCF-derived value of $305.46 per share, with trailing free cash flow near $4 billion. Wyndham Hotels ended at $81.11, roughly 27% under its $110.96 intrinsic value. HORIBA trades at ¥16,470, near SWS fair value, with earnings up 13.6% year over year. Manulife TERM:CA received updated AI trading signals, with ratings Neutral across all horizons.
9 January 2026
···
P&G stock rises after Crest toothpaste label deal in Texas puts PG back in focus

P&G stock rises after Crest toothpaste label deal in Texas puts PG back in focus

Procter & Gamble shares rose 2.5% to $141.53 after agreeing with Texas officials to change Crest children’s toothpaste packaging to clarify dosing. The rollout began Jan. 1, with P&G required to comply for five years. Piper Sandler started coverage at Neutral with a $150 target; TD Cowen cut its target to $150. Investors await Friday’s U.S. jobs report and P&G’s earnings on Jan. 22.
9 January 2026
·
D-Wave Quantum stock slips as $550 million Quantum Circuits deal puts dilution in focus

D-Wave Quantum stock slips as $550 million Quantum Circuits deal puts dilution in focus

D-Wave Quantum shares fell 3.1% Thursday after announcing a $550 million cash-and-stock deal to acquire Quantum Circuits. The stock traded between $28.66 and $30.44 on volume of 38.7 million shares. The deal’s stock portion uses a 10-day VWAP with a collar between $22.30 and $39.03 per share. Closing is expected in late January, pending antitrust review and shareholder approval.
9 January 2026
··
Why Qualcomm stock moved: Volkswagen’s 2027 chip plan and Samsung 2nm talks

Why Qualcomm stock moved: Volkswagen’s 2027 chip plan and Samsung 2nm talks

Qualcomm shares rose 0.9% to $181.87 Thursday after Volkswagen named it main chip supplier for a new software platform launching in 2027. The stock traded between $176.51 and $184.29. Qualcomm is also in talks with Samsung to manufacture chips using a two-nanometre process. Investors await Friday’s U.S. jobs report and Qualcomm’s Feb. 4 earnings.
9 January 2026
·····
UnitedHealth stock rises as lawmakers summon insurers; UNH earnings date now in focus

UnitedHealth stock rises as lawmakers summon insurers; UNH earnings date now in focus

U.S. House committees summoned UnitedHealth and four other insurers to testify on coverage affordability Jan. 22. UnitedHealth shares rose 1.5% to $346.85 after Wolfe Research raised its price target to $400. The company reports 2025 earnings and 2026 guidance Jan. 27. Senators also accused UnitedHealth of withholding documents in a nursing home care probe.
9 January 2026
·····
Goldman Sachs stock slips after Apple Card handoff to JPMorgan — what Wall Street watches next

Goldman Sachs stock slips after Apple Card handoff to JPMorgan — what Wall Street watches next

Goldman Sachs will transfer the Apple Card program to JPMorgan Chase over 24 months, ending its role as issuer. Goldman expects a $0.46 boost to Q4 2025 EPS, offset by $2.26 billion in loan markdowns and contract costs. GS shares fell 0.66% to $934.83 Thursday. JPMorgan said it will take on over $20 billion in card balances and book a $2.2 billion credit loss provision.
9 January 2026
····
Seagate stock tumbles nearly 8% as AI-storage trade cools ahead of payrolls

Seagate stock tumbles nearly 8% as AI-storage trade cools ahead of payrolls

Seagate shares dropped 7.7% to $284.47 on Thursday, deepening a two-day slide among storage stocks as investors reduced tech exposure ahead of Friday’s U.S. jobs report. SanDisk fell 5.4% and Western Digital lost 6.1%. A U.S. appeals court revived Seagate’s antitrust claims against NHK Spring after the close. Seagate reports earnings January 20 and guided for Q2 revenue of $2.70 billion.
9 January 2026
···
1 … 587 588 589 590 591 … 1,363

Stock Market Today

  • Sarepta Therapeutics Shares Surge After Early siRNA Trial Results Amid Valuation Debate
    March 26, 2026, 4:36 AM EDT. Sarepta Therapeutics (SRPT) shares jumped nearly 35% in one day following early Phase 1/2 results for siRNA therapies targeting rare neuromuscular diseases. Despite this rebound to $23.77, the stock is down 67% over the past year, reflecting long-term investor caution. Analyst consensus values Sarepta at $20.61, showing it as overvalued by 15%. However, Simply Wall St's discounted cash flow (DCF) model suggests a 69.8% undervaluation, estimating fair value at $78.79. The disparity hinges on Sarepta's pipeline potential, including gene therapy Elevidys, ongoing regulatory risks, and high research costs that resulted in a $713 million loss. Investors face a critical choice between optimistic growth pricing and conservative risk assessment amid volatile biotech sector dynamics.
Go toTop